Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:CRSP NASDAQ:EWTX NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$121.71-0.7%$116.84$75.56▼$139.13$6.11B0.52483,518 shs326,702 shsCRSPCRISPR Therapeutics$73.07-2.5%$59.14$30.04▼$78.48$6.81B1.842.88 million shs3.83 million shsEWTXEdgewise Therapeutics$15.11-5.9%$14.59$10.60▼$38.12$1.69B0.281.03 million shs771,683 shsRYTMRhythm Pharmaceuticals$100.82+0.6%$98.57$45.90▼$106.52$6.66B2.12606,948 shs492,692 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-0.66%+1.17%-1.94%+11.68%+45.69%CRSPCRISPR Therapeutics-2.47%+7.87%+41.03%+28.64%+60.94%EWTXEdgewise Therapeutics-5.86%-3.45%+3.00%+9.18%-50.18%RYTMRhythm Pharmaceuticals+0.61%+1.82%+0.55%+16.29%+111.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$121.71-0.7%$116.84$75.56▼$139.13$6.11B0.52483,518 shs326,702 shsCRSPCRISPR Therapeutics$73.07-2.5%$59.14$30.04▼$78.48$6.81B1.842.88 million shs3.83 million shsEWTXEdgewise Therapeutics$15.11-5.9%$14.59$10.60▼$38.12$1.69B0.281.03 million shs771,683 shsRYTMRhythm Pharmaceuticals$100.82+0.6%$98.57$45.90▼$106.52$6.66B2.12606,948 shs492,692 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-0.66%+1.17%-1.94%+11.68%+45.69%CRSPCRISPR Therapeutics-2.47%+7.87%+41.03%+28.64%+60.94%EWTXEdgewise Therapeutics-5.86%-3.45%+3.00%+9.18%-50.18%RYTMRhythm Pharmaceuticals+0.61%+1.82%+0.55%+16.29%+111.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.00Buy$177.9346.19% UpsideCRSPCRISPR Therapeutics 2.42Hold$71.50-2.15% DownsideEWTXEdgewise Therapeutics 2.69Moderate Buy$38.83157.00% UpsideRYTMRhythm Pharmaceuticals 2.94Moderate Buy$106.645.78% UpsideCurrent Analyst Ratings BreakdownLatest EWTX, RYTM, CRSP, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$81.0010/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025EWTXEdgewise TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RYTMRhythm PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/30/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/29/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.009/27/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025EWTXEdgewise TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M15.75N/AN/A$1.18 per share103.14CRSPCRISPR Therapeutics$37.31M178.12N/AN/A$22.64 per share3.23EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ARYTMRhythm Pharmaceuticals$130.13M51.46N/AN/A$0.35 per share288.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A43.16N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)Latest EWTX, RYTM, CRSP, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025EWTXEdgewise Therapeutics-$0.40N/AN/AN/AN/AN/A11/4/2025Q3 2025CRSPCRISPR Therapeutics-$1.32N/AN/AN/A$8.74 millionN/A11/4/2025Q3 2025RYTMRhythm Pharmaceuticals-$0.72N/AN/AN/A$50.71 millionN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51CRSPCRISPR TherapeuticsN/A16.6116.61EWTXEdgewise TherapeuticsN/A28.8728.87RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%CRSPCRISPR Therapeutics69.20%EWTXEdgewise TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%CRSPCRISPR Therapeutics4.30%EWTXEdgewise Therapeutics23.20%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableEWTX, RYTM, CRSP, and AXSM HeadlinesRecent News About These CompaniesLeo Wealth LLC Has $850,000 Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTMOctober 10 at 5:04 AM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9 at 4:58 AM | marketbeat.comShould You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead?October 3, 2025 | insidermonkey.comHC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy RecommendationSeptember 29, 2025 | msn.comJMP Securities Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform RecommendationSeptember 26, 2025 | msn.comRhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMPSeptember 25, 2025 | msn.comJMP Securities Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock PriceSeptember 25, 2025 | marketbeat.comRhythm Pharmaceuticals price target raised to $122 from $109 at Morgan StanleySeptember 24, 2025 | msn.comRhythm Pharmaceuticals, Inc. (RYTM) Discusses On Commercial Readiness For Acquired Hypothalamic Obesity Event Call (Transcript)September 24, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. - Special CallSeptember 24, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Discusses on Commercial Readiness for Acquired Hypothalamic Obesity EventSeptember 24, 2025 | seekingalpha.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $138.00 at The Goldman Sachs GroupSeptember 24, 2025 | marketbeat.com3 Stocks That May Be Undervalued By Up To 49%September 23, 2025 | finance.yahoo.comRhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Wedge Capital Management L L P NCSeptember 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $15.04 Million Position in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 23, 2025 | marketbeat.comToth Financial Advisory Corp Takes $632,000 Position in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 22, 2025 | marketbeat.com2 Under-the-Radar Stocks That Could SoarSeptember 21, 2025 | fool.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 20, 2025 | marketbeat.comVoya Investment Management LLC Cuts Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 20, 2025 | marketbeat.comStrs Ohio Invests $980,000 in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 19, 2025 | marketbeat.comHarbor Capital Advisors Inc. Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX, RYTM, CRSP, and AXSM Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$121.71 -0.81 (-0.66%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$122.76 +1.05 (+0.86%) As of 10/10/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.CRISPR Therapeutics NASDAQ:CRSP$73.07 -1.85 (-2.47%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$72.12 -0.95 (-1.30%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Edgewise Therapeutics NASDAQ:EWTX$15.11 -0.94 (-5.86%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$14.85 -0.26 (-1.72%) As of 10/10/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Rhythm Pharmaceuticals NASDAQ:RYTM$100.82 +0.61 (+0.61%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$100.87 +0.05 (+0.05%) As of 10/10/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
